ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Rational Design of Natural Xanthones Against Gram-negative Bacteria.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- The Role of Natural Flavonoid Quercetin in Combating Tet(X3)/Tet(X4)-Positive Bacterial Infections.Microorganisms · 2026Article
- Copper ions restore antibacterial activity of tigecycline by regulating photodegradation pathway under light exposure.Communications biology · 2026Article
- Antibacterial Activity and Action Mode of Lactobionic Acid AgainstFoods (Basel, Switzerland) · 2026Article
- Novel Antifungal Scaffold Targeting Tubulin Overcomes Sclerotinia Sclerotiorum Resistance.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Overcoming Methicillin-ResistantResearch (Washington, D.C.) · 2026Article
- Effect of mangosteen peel extract nanocapsule on the hematological profile and total bacterial count in broiler chickens experimentally infected with avian pathogenicOpen veterinary journal · 2026Article
- Bakuchiol, a Natural Antioxidant, Synergizes with Colistin Against Multidrug-Resistant Gram-Negative Bacteria by Disrupting Iron Homeostasis and Membrane Integrity.Antioxidants (Basel, Switzerland) · 2025Article
- Natural flavonoids combat cytosolic MRSA by potentiating phagosome acidification.Cell communication and signaling : CCS · 2025Article
- Rational Design of Natural Xanthones Against Gram-negative Bacteria.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Xanthone Dimers in Angiosperms, Fungi, Lichens: Comprehensive Review of Their Sources, Structures, and Pharmacological Properties.Molecules (Basel, Switzerland) · 2025Review
- High Stability and Low Irritation of Enrofloxacin-Colistin Combination Injection Through a Tripartite Strategy.Drug design, development and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Most antibiotics are ineffective against Gram-negative bacteria owing to the existence of the outer membrane (OM) barrier. The rational design of compounds to expand their antibacterial spectra of antibiotics solely targeting Gram-positive pathogens remains challenging. Here, the design of skeletons from natural products to penetrate the OM are deciphered. Structure-activity relationship analysis shows the optimization of the model of natural xanthones α-mangostin endows the broad-spectrum antibacterial activity. Mechanistic studies demonstrate the lead compound A20 penetrates the OM in a self-promoted pathway through electronic and hydrophobic interactions with lipopolysaccharides and phospholipids in OM. A20 displays rapid bactericidal activity by targeting the cofactor heme in the respiratory complex. The therapeutic efficacy of A20 is demonstrated in two animal models infected with multidrug-resistant Gram-negative bacterial pathogens. The findings elucidate the structural property and self-promoted transportation of a class of antibacterial compounds, to facilitate the design and discovery of antibacterial agents against increasingly prevalent Gram-negative pathogens associated with infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.